Format

Send to

Choose Destination
Exp Cell Res. 2011 May 15;317(9):1286-92. doi: 10.1016/j.yexcr.2011.02.017. Epub 2011 Mar 22.

Inhibition of IL6 in rheumatoid arthritis and juvenile idiopathic arthritis.

Author information

1
The University of California, San Diego, CA, USA.

Abstract

A number of clinical trials have been done to investigate the role of interleukin-6 (IL-6) as a potential therapeutic target in rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA). Most of the data testing this comes from trials of the humanized anti Il-6 receptor antibody tocilizumab. Results from clinical trials worldwide have been promising so far. Additional study will define the ultimate role of tocilizumab and Il6 inhibitors in the treatment paradigms for RA and JIA.

PMID:
21439276
DOI:
10.1016/j.yexcr.2011.02.017
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center